阿立哌唑治疗精神分裂症40例

Treatment of 40 Cases of Schizophrenia with Aripiprazole

目的 评价阿立哌唑对精神分裂症的疗效与安全性.方法 80例精神分裂症患者随机分为2组：治疗组和对照组各40例,分别给予阿立哌唑10～20 mg·d^-1,po,qd;氯氮平300～ 500 mg·d^-1,po,bid.采用阳性症状与阴性症状量表（PANSS）评价临床疗效,不良反应症状量表（TESS）评价不良反应,观察8周.结果 治疗组PANSS总分减分率为50.4%,有效率为87.5%;对照组PANSS总分减分率为49.4%,有效率为85.0%.两组总体疗效相当（P＞0.05）.阿立哌唑对阴性症状起效较早.治疗组过度镇静、流延、便秘、体重增加等不良反应发生率低于对照组（P＜0.05或＜0.01）.结论 阿立哌唑治疗精神分裂症安全有效.

Objective To appraise the therapeutic effectiveness and safety rate of aripiprazole in the treatment of schizophrenia. Methods 80 patients with schizophrenia were randomly divided into two equal groups： the trial group and control group. Patients of these 2 groups were given each 10 - 20 mg·d^-1 of aripiprazole PO, q. d. and 300 - 500 mg·d^-1 of clozapine, PO, b. i. d, respectively. The course of treatment in both groups lasted 8 weeks. The therapeutic effectiveness was assessed with the Positive and Negative Syndrome Scale （ PANSS）, while adverse reactions were appraised with the Treatment Emergent Symptom Scale （TESS）. Results The reduction rate of PANSS total scores and the effective rate in patients of the trial group were 50.4% and the 87.5%, respectively, while those in patients of the control group were 49. 4% and 85.0%, respectively. The overall curative effects were similar in patients of the two groups （P 〉0. 05）. Aripiprazole started earlier to act upon negative symptoms as compared with clozapine. The incidences of adverse reactions including oversedation, salivation, constipation, weight gaining etc. in patients of the trial group were significantly lower than those in patients of the control group （ P 〈 0.05 or P 〈 0.01 ）. Conclusion Aripiprazole was shown to be safe and effective in the treatment of schizophrenia.